Commercial/Healthcare Exchange PA Criteria

Effective: January 1, 2020

Prior Authorization: Vitamin D2 Analogs

Products Affected: doxercalciferol oral capsule, paricalcitol oral capsule

Medication Description:
Doxercalciferol and paricalcitol oral capsules are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Covered Uses:
1. doxercalciferol
    a. Secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis
    b. Secondary hyperparathyroidism in patients with stage 3 or 4 CKD (patient is not on dialysis).
2. paricalcitol
    a. Prevention and treatment in adults and pediatric patients 5 years and older with secondary hyperparathyroidism associated with stage 3 and 4 CKD and stage 5 CKD patients on hemodialysis or peritoneal dialysis.

Exclusion Criteria:
1. Hypercalcemia
2. Vitamin D toxicity

Required Medical Information:
1. Diagnosis
2. Previous therapies tried/failed

Age Restrictions:
doxercalciferol capsule: 18 years of age and older
paricalcitol capsule: 10 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:
1. Patient has a diagnosis of secondary hyperparathyroidism; AND
2. Patient has a documented intolerance, contraindication, or treatment failure with, an adequate trial with ergocalciferol, cholecalciferol, or calcitriol.

References:

1. Product Information: HECTOROL(R) Oral Capsules, doxercalciferol oral capsules. Genzyme Corporation, Middleton, WI, 2004.
2. Product Information: ZEMPLAR(R) oral capsules, paricalcitol oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2016.

ConnectiCare

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/21/2019